Anti-citrullinated protein antibodies have a low avidity compared with antibodies against recall antigens

Annals of the Rheumatic Diseases

Volumn 70, Issue 2, 2011, Pages 373-379

  Suwannalai, P ^a   Scherer, H U ^a   Van Der Woude, D ^a   Ioan Facsinay, A ^a   Jol van Der Zijde, C M ^a   Van Tol, M J D ^a   Drijfhout, J W ^a   Huizinga, T W J ^a   Toes, R E M ^a   Trouw, L A ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; AUTOANTIBODY; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; DIPHTHERIA TETANUS TOXOID; ISOTOPE;

ADULT; AGED; ANTIBODY RESPONSE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENE SWITCHING; HUMAN; ISOTOPE SWITCHING; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, BACTERIAL; ANTIBODY AFFINITY; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; DIPHTHERIA TOXOID; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOLOGIC MEMORY; MALE; MIDDLE AGED; PEPTIDES, CYCLIC; TETANUS TOXOID; YOUNG ADULT;

EID: 78751701595     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2010.135509     Document Type: Article

References (31)

1. Vincent C, Nogueira L, Clavel C, et al. Autoantibodies to citrullinated proteins: ACPA. Autoimmunity 2005;38:17-24.
2. Klareskog L, Rönnelid J, Lundberg K, et al. Immunity to citrullinated proteins in rheumatoid arthritis. Annu Rev Immunol 2008;26:651-75. (Pubitemid 351600388)
3. Kroot EJ, de Jong BA, van Leeuwen MA, et al. The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis Rheum 2000;43:1831-5.
4. van der Helm-van Mil AH, Verpoort KN, Breedveld FC, et al. Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis. Arthritis Res Ther 2005;7:R949-58.
5. Nielen MM, van Schaardenburg D, Reesink HW, et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 2004;50:380-6.
6. Kuhn KA, Kulik L, Tomooka B, et al. Antibodies against citrullinated proteins enhance tissue injury in experimental autoimmune arthritis. J Clin Invest 2006;116:961-73.
7. Uysal H, Bockermann R, Nandakumar KS, et al. Structure and pathogenicity of antibodies specific for citrullinated collagen type II in experimental arthritis. J Exp Med 2009;206:449-62.
8. Clavel C, Nogueira L, Laurent L, et al. Induction of macrophage secretion of tumor necrosis factor alpha through Fcgamma receptor IIa engagement by rheumatoid arthritis-specific autoantibodies to citrullinated proteins complexed with fibrinogen. Arthritis Rheum 2008;58:678-88. (Pubitemid 351364865)
9. Trouw LA, Haisma EM, Levarht EW, et al. Anti-cyclic citrullinated peptide antibodies from rheumatoid arthritis patients activate complement via both the classical and alternative pathways. Arthritis Rheum 2009;60:1923-31.
10. Aboud S, Matre R, Lyamuya EF, et al. Levels and avidity of antibodies to tetanus toxoid in children aged 1-15 years in Dar es Salaam and Bagamoyo, Tanzania. Ann Trop Paediatr 2000;20:313-22.
11. Usinger WR, Lucas AH. Avidity as a determinant of the protective efficacy of human antibodies to pneumococcal capsular polysaccharides. Infect Immun 1999;67:2366-70.
12. Breukels MA, Jol-van der Zijde E, van Tol MJ, et al. Concentration and avidity of anti-Haemophilus influenzae type b (Hib) antibodies in serum samples obtained from patients for whom Hib vaccination failed. Clin Infect Dis 2002;34:191-7.
13. Huang H, Benoist C, Mathis D. Rituximab specifically depletes short-lived autoreactive plasma cells in a mouse model of inflammatory arthritis. Proc Natl Acad Sci USA 2010;107:4658-63.
14. van Aken J, van Dongen H, le Cessie S, et al. Comparison of long term outcome of patients with rheumatoid arthritis presenting with undifferentiated arthritis or with rheumatoid arthritis: an observational cohort study. Ann Rheum Dis 2006;65:20-5.
15. Pullen GR, Fitzgerald MG, Hosking CS. Antibody avidity determination by ELISA using thiocyanate elution. J Immunol Methods 1986;86:83-7.
16. Goldblatt D. Simple solid phase assays of avidity. In: Turner MW, Johnson AP, eds. Immunochemistry II: A Practical Approach. Oxford: Oxford University Press, 1997: 31.
17. Perciani CT, Peixoto PS, Dias WO, et al. Improved method to calculate the antibody avidity index. J Clin Lab Anal 2007;21:201-6.
18. Chapuy-Regaud S, Nogueira L, Clavel C, et al. IgG subclass distribution of the rheumatoid arthritis-specific autoantibodies to citrullinated fibrin. Clin Exp Immunol 2005;139:542-50. (Pubitemid 40333267)
19. Kroon FP, van Tol MJ, Jol-van der Zijde CM, et al. Immunoglobulin G (IgG) subclass distribution and IgG1 avidity of antibodies in human immunodeficiency virus-infected individuals after revaccination with tetanus toxoid. Clin Diagn Lab Immunol 1999;6:352-5.
20. Cohen D, Green MS, Katzenelson E, et al. Long-term persistence of anti-diphtheria toxin antibodies among adults in Israel. Implications for vaccine policy. Eur J Epidemiol 1994;10:267-70. (Pubitemid 24315553)
21. Verpoort KN, Jol-van der Zijde CM, Papendrecht-van der Voort EA, et al. Isotype distribution of anti-cyclic citrullinated peptide antibodies in undifferentiated arthritis and rheumatoid arthritis reflects an ongoing immune response. Arthritis Rheum 2006;54:3799-808.
22. Pruijn GJ, Wiik A, van Venrooij WJ. The use of citrullinated peptides and proteins for the diagnosis of rheumatoid arthritis. Arthritis Res Ther 2010;12:203.
23. Bang H, Egerer K, Gauliard A, et al. Mutation and citrullination modifies vimentin to a novel autoantigen for rheumatoid arthritis. Arthritis Rheum 2007;56:2503-11.
24. Masson-Bessière C, Sebbag M, Girbal-Neuhauser E, et al. The major synovial targets of the rheumatoid arthritis-specific antifilaggrin autoantibodies are deiminated forms of the alpha- and beta-chains of fibrin. J Immunol 2001;166:4177-84. (Pubitemid 32224951)
25. Snir O, Widhe M, von Spee C, et al. Multiple antibody reactivities to citrullinated antigens in sera from patients with rheumatoid arthritis: association with HLA-DRB1 alleles. Ann Rheum Dis 2009;68:736-43.
26. Andersson B. Studies on the regulation of avidity at the level of the single antibody-forming cell. The effect of antigen dose and time after immunization. J Exp Med 1970;132:77-88.
27. Schuerwegh AJ, Ioan-Facsinay A, Dorjée AL, et al. Evidence for a functional role of IgE anticitrullinated protein antibodies in rheumatoid arthritis. Proc Natl Acad Sci USA 2010;107:2586-91.
28. DiSanto JP, Bonnefoy JY, Gauchat JF, et al. CD40 ligand mutations in x-linked immunodeficiency with hyper-IgM. Nature 1993;361:541-3.
29. Korthäuer U, Graf D, Mages HW, et al. Defective expression of T-cell CD40 ligand causes X-linked immunodeficiency with hyper-IgM. Nature 1993;361:539-41.
30. van der Helm-van Mil AH, Verpoort KN, Breedveld FC, et al. The HLA-DRB1 shared epitope alleles are primarily a risk factor for anti-cyclic citrullinated peptide antibodies and are not an independent risk factor for development of rheumatoid arthritis. Arthritis Rheum 2006;54:1117-21.
31. Vora KA, Wang LC, Rao SP, et al. Cutting edge: germinal centers formed in the absence of B cell-activating factor belonging to the TNF family exhibit impaired maturation and function. J Immunol 2003;171:547-51.